APA (7th ed.) Citation

Qiu, D., Wang, T., Xiong, Y., Li, K., Qiu, X., Feng, Y., . . . Jia, C. (2024). TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis, 13(1), 1. https://doi.org/10.1038/s41389-024-00534-1

Chicago Style (17th ed.) Citation

Qiu, Dongbo, et al. "TFCP2L1 Drives Stemness and Enhances Their Resistance to Sorafenib Treatment by Modulating the NANOG/STAT3 Pathway in Hepatocellular Carcinoma." Oncogenesis 13, no. 1 (2024): 1. https://doi.org/10.1038/s41389-024-00534-1.

MLA (9th ed.) Citation

Qiu, Dongbo, et al. "TFCP2L1 Drives Stemness and Enhances Their Resistance to Sorafenib Treatment by Modulating the NANOG/STAT3 Pathway in Hepatocellular Carcinoma." Oncogenesis, vol. 13, no. 1, 2024, p. 1, https://doi.org/10.1038/s41389-024-00534-1.